News
Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a ...
PTC Therapeutics faces pivotal FDA decisions for approvals that could potentially transform their long-term revenues. Click ...
Donald Trump reportedly ignored calls from Health Secretary Robert F. Kennedy Jr. not to fire the top vaccine official at the ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.
23h
TipRanks on MSNSarepta Stock (SRPT) Rallies on FDA Nod for Broader Gene Therapy UseShares of Sarepta Therapeutics ($SRPT) jumped over 14% on Tuesday after the FDA authorized the company to restart shipments ...
From the meme stock revival to Trump's Fed feud, Peter Hodson looks at some of the summer's more bizarre trends ...
Other changes under Prasad, who was also the agency's chief medical and science officer, included a new policy limiting the ...
22hon MSN
The president overruled his HHS secretary and FDA chief, four people with knowledge of the decision tell POLITICO.
8h
India Today on MSNWhat forced Vinay Prasad to exit top job at US FDA in just 3 monthsIndian-origin scientist Vinay Prasad resigned as the FDA's vaccine and gene therapy chief in just three months after backlash ...
The U.S. Food and Drug Administration's (FDA) top vaccine official is stepping down after just three months in a role that ...
Prasad, a longtime critic of the FDA’s leniency in drug approvals, joined the agency in May. WASHINGTON — The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results